Aripiprazole in the treatment of delirium

Psychosomatics

Volumn 47, Issue 5, 2006, Pages 385-391

  Straker, David A ^a,b   Shapiro, Peter A ^a   Muskin, Philip R ^a  

^a NewYork Presbyterian Hospital

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; LIPID; OLANZAPINE; QUETIAPINE; RISPERIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DELIRIUM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MALE; QT INTERVAL; RATING SCALE; CLINICAL TRIAL; DOSE RESPONSE; HOSPITALIZATION; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DELIRIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33749235300     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.47.5.385     Document Type: Article

References (50)

1. Sipahimalani A, Masand PS: Olanzapine in the treatment of delirium. Psychosomatics 1998; 39:422-430
2. Trzepacz PT, Meagher DJ, Wise MG: Neuropsychiatric aspects of delirium, in The American Psychiatric Publishing Textbook of Neuropsychiatry and Clinical Neurosciences. Edited by Yudofsky SC, Hales RE. Washington, DC, American Psychiatric Publishing, 2002, pp 525-564
3. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies. Am J Psychiatry 2004; 161:414-425
4. Schwartz TL, Masand PS: The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002; 43:171-174
5. Kim KS, Pae CU, Chae JH, et al: An open pilot trial of olanzapine for delirium in the Korean population. Psychiatry Clin Neurosci 2001; 55:515-519
6. Skrobik YK, Bergeron N, Dumont M, et al: Olanzapine versus haloperidol: treating delirium in a critical care setting. Intens Care Med 2004; 30:444-449
7. Sipahimalani A, Masand PS: Olanzapine in the treatment of delirium. Psychosomatics 1998; 39:422-430
8. Han CS, Kim YK: A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004; 45:297-301
9. Parellada E, Baeza I, de Pablo J, et al: Risperidone in the treatment of patients with delirium. J Clin Psychiatry 2004; 65:348-353
10. Pae CU, Lee SJ, Lee CU, et al: A pilot trial of quetiapine for the treatment of patients with delirium. Hum Psychopharmacol 2004; 19:125-127
11. Sasaki Y, Matsuyama T, Inoue S, et al: A prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. J Clin Psychiatry 2003; 64:1316-1321
12. Kim KY, Bader GM, Kotlyar V, et al: Treatment of delirium with quetiapine in older adults. J Geriatr Psychiatry Neurol 2003; 16:29-31
13. Sipahimalani A, Masand PS: Use of risperidone in delirium: case reports. Ann Clin Psychiatry 1997; 9:105-107
14. Sipahimalani A, Sime RM, Masand PS: Treatment of delirium with risperidone: case reports. Int J Geriatr Psychopharmacol 1997; 1:24-26
15. Ravona-Springer R, Dolberg O, Hirschmann S, et al: Delirium in elderly patients treated with risperidone: a report of three cases. J Clin Psychopharmacol 1998; 18:171-172
16. Schwartz TL, Masand PS: Treatment of delirium with quetiapine. J Clin Psychiatry (Primary Care Companion) 2000; 2:10-12
17. Leso L, Schwartz TL: Ziprasidone treatment of delirium. Psychosomatics 2002; 43:61-62
18. Horikawa N, Yamazaki T, Miyamoto K, et al: Treatment for delirium with risperidone: results of a prospective, open trial with 10 patients. Gen Hosp Psychiatry 2003; 25:289-292
19. Breitbart W, Tremblay A, Gibson C: An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 2002; 43:175-182
20. Marder SR, McQuade RD, Stock E, et al: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61:123-136
21. McQuade RD, Jody D, Kujawa MJ, et al: Long-term weight effects of aripiprazole versus olanzapine. Poster presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 17-22, 2003
22. Marder SR, Kaplita S, Saha AR, et al: Glycemic control and plasma lipids in long-term aripiprazole treatment. Poster presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 17-22, 2003
23. Weiden PJ, Waldeck R, Tafesse E, et al: Aripiprazole is not associated with increased diabetes risk: a long-term model. Poster presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 17-22, 2003
24. Casey DE, L'Italien G, Waldeck R, et al: Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo. Poster presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 17-22, 2003
25. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Text Revision. Washington, DC, American Psychiatric Association, 2000, pp 136-147
26. Trzepacz PT, Mittal D, Torres R, et al: Validation of the Delirium Rating Scale-Revised-98: comparison with the Delirium Rating Scale and the Cognitive Test for Delirium. J Neuropsychiatry Clin Neurosci 2001; 13:229-242
27. National Institute of Mental Health: CGI: Clinical Global Impressions, in Manual for the ECDEU Assessment Battery-2, Revised Edition. Edited by Guy W, Bonato RR. Bethesda. MD, National Institute of Mental Health, 1970, 12:112-116
28. Allison DB, Mentore JL, Heo M, et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696
29. McIntyre RS, Trakas K, Lin D, et al: Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry 2003; 48:689-694
30. Wirshing DA, Boyd JA, Meng LR, et al: The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856-865
31. Newcomer JW, Haupt DW, Fucetola R, et al: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59:337-345
32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001; 285:2486-2497
33. Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged Q-Tc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158:1774-1782
34. Liperoti R, Gambassi G, Lapane KL, et al: Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med 2005; 165:696-701
35. Clinical psychiatry in the nursing home, in The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 3rd Edition. Edited by Blazer DG, Steffens DC. Busse EW. Washington. DC, American Psychiatric Publishing, 2004, pp 485-489
36. Brauer C, Morrison RS, Silberzweig SB, et al: The cause of delirium in patients with hip fracture. Arch Intern Med 2000; 160:1856-1860
37. Marcantonio ER, Flacker JM, Michaels M, et al: Delirium is independently associated with poor functional recovery after hip fracture. J Am Geriatr Soc 2000; 48:618-624
38. O'Keeffe S, Lavan J: The prognostic significance of delirium in older hospital patients. J Am Geriatr Soc 1997; 45:174-178
39. Levkoff SE, Evans DA, Liptzin B, et al: Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med 1992; 152:334-340
40. Schizophrenia and paranoid disorders, in The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 3rd Edition. Edited by Blazer DG, Steffens DC, Busse EW. Washington, DC, American Psychiatric Publishing, 2004, pp 274-277
41. Gill SS, Rochon PA, Herrmann N, et al: Atypical antipsychotic drugs and risk of ischemic stroke: population-based, retrospective cohort study. BMJ 2005; 330(7489):445 (E-pub: 1/24/05)
42. Hermann N, Mamdani M, Lanctot KL: Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161:1113-1115
43. Smith DA, Beier MT: Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc 2004; 5:129-132
44. Wooltorton E: Risperidone (Risperdal®): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167:1269-1270
45. http://www.fda.gov/cder/drug/advisory/andpsychotics.htm. (April 11, 2005)
46. De Deyn P, Jeste D, Auby P, et al: Aripiprazole in dementia of the Alzheimer's type. Poster presented at the European College of Neuropsychiatry, Stockholm. Sweden, October 10-13, 2004
47. Kostic D, Breder C, Rene-Swanink R, et al: A dose-ranging study of aripiprazole treatment in patients with psychosis associated with Alzheimer's dementia. Poster presented at the Congress of the European College of Neuropsychopharmacology, Stockholm, Sweden, October 9-13, 2004
48. Stock E, Breder C, Goyvaerts H, et al: Safety profile of aripiprazole in psychosis of Alzheimer's dementia: pooled analysis. Poster presented at the American Psychiatric Association Annual Meeting, New York, NY, May 1-6, 2004
49. Streim JE, Breder C, Swanink R, et al: Flexible-dose aripiprazole in psychosis of Alzheimer's dementia (AD). Poster presented at the American Psychiatric Association Annual Meeting, New York, NY, May 1-6, 2004
50. Package Insert: Abilify® (aripiprazole). Bristol-Myers Squibb, Revised March 2005